DNA‐methylation analysis identifies the E‐cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies
Open Access
- 2 June 2004
- Vol. 100 (12), 2598-2606
- https://doi.org/10.1002/cncr.20295
Abstract
BACKGROUND Silencing of tumor suppressor genes (TSG) by aberrant methylation (referred to as methylation) contributes to the pathogenesis of various human malignancies. However, little is known about the methylation of known and putative TSGs in monoclonal gammopathies. Thus, the authors investigated the methylation frequencies of 10 genes in patients with monoclonal gammopathies. METHODS The methylation patterns of the genes p16INK4a (p16), tissue inhibitor of metalloproteinase 3 (TIMP3), p15INK4b (p15), E‐cadherin (ECAD), death‐associated protein kinase (DAPK), p73, RAS‐association domain family 1A (RASSF1A), p14, O6‐methylguanine DNA methyltransferase (MGMT), and retinoid acid receptor β2 (RARβ) were determined in patients with monoclonal gammopathy of undetermined significance (MGUS; n = 29), smoldering multiple myeloma (SMM; n = 5), multiple myeloma (MM; n = 113), or plasma cell leukemia (PCL; n = 7) by methylation‐specific polymerase chain reaction analysis. RESULTS Methylation frequencies for p16, TIMP3, p15, ECAD, DAPK, p73, RASSF1A, p14, MGMT, and RARβ were as follows: 28%, 35%, 10%, 0%, 17%, 21%, 14%, 14%, 7%, and 0%, respectively, in patients with MGUS and 36%, 29%, 27%, 27%, 22%, 15%, 15%, 9%, 4%, and 0%, respectively, in patients with MM. Methylation of at least 1 of these genes was detected in 79% of patients with MGUS and in 80% of patients with MM. Although methylation of ECAD was not detected in patients with MGUS, it was observed frequently in patients with MM and with even greater frequency in patients with PCL. It is noteworthy that an association was found between ECAD methylation and poor prognostic markers in patients with MM. CONCLUSIONS Methylation of certain genes can be detected frequently in patients with monoclonal gammopathies. The current data suggest that methylation of ECAD is a marker of disease progression in patients with MM and PCL. Cancer 2004. © 2004 American Cancer Society.Keywords
Funding Information
- Austrian Science Fund (P16283-B08)
- Jubiläumsfonds of the Austrian National Bank (7760)
This publication has 36 references indexed in Scilit:
- Aberrant DNA methylation ofp57KIP2 gene in the promoter region in lymphoid malignancies of B-cell phenotypeBlood, 2002
- A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined SignificanceNew England Journal of Medicine, 2002
- p16 INK4a andp15INK4b gene methylations in plasma cells from monoclonal gammopathy of undetermined significanceBlood, 2001
- Methylation profiling in acute myeloid leukemiaBlood, 2001
- Correlations of partial and extensive methylation at the p14ARF locus with reduced mRNA expression in colorectal cancer cell lines and clinicopathological features in primary tumorsCarcinogenesis: Integrative Cancer Research, 2000
- Promoter Methylation and Silencing of the Retinoic Acid Receptor- Gene in Lung CarcinomasJNCI Journal of the National Cancer Institute, 2000
- Status of methylation of p16 gene in multiple myeloma: a comparative study of three methods for its detectionClinical Biochemistry, 2000
- The biology of multiple myelomaZeitschrift für Krebsforschung und Klinische Onkologie, 2000
- Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.Proceedings of the National Academy of Sciences, 1996
- 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancersNature Medicine, 1995